Den europeiske union - engelsk - EMA (European Medicines Agency)

valneva austria gmbh - japanese-encephalitis virus, inactivated (attenuated strain sa14-14-2 grown in vero cells) - encephalitis, japanese; immunization - vaccines - ixiaro is indicated for active immunisation against japanese encephalitis in adults, adolescents, children and infants aged two months and older.ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tick-borne encephalitis virus (inactivated) neudoerfl - suspension for injection in pre-filled syringe - 0.25 millilitre(s) - encephalitis vaccines; encephalitis, tick borne, inactivated, whole virus - encephalitis vaccines - it is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (tbe).

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tbe virus antigen - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - encephalitis vaccines; encephalitis, tick borne, inactivated, whole virus - encephalitis vaccines - it is indicated for the active (prophylactic) immunization of persons of 16 years of age and older against tick-borne encephalitis (tbe).

USA - engelsk - NLM (National Library of Medicine)

valneva scotland ltd. - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml - ixiaro is a vaccine indicated for the prevention of disease caused by japanese encephalitis virus (jev). ixiaro is approved for use in individuals 2 months of age and older. severe allergic reaction (e.g., anaphylaxis) after a previous dose of ixiaro, any other japanese encephalitis virus vaccine, or any component of ixiaro, including protamine sulfate, is a contraindication to administration of ixiaro [see description (11)]. alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with ixiaro is considered. pregnancy category b. reproduction studies have been performed in female rats at doses approximately 300-fold excess relative to the projected human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to ixiaro. there are, however, no adequate and well‑controlled

USA - engelsk - NLM (National Library of Medicine)

vetter pharma fertigung gmbh & co. kg - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml

Israel - engelsk - Ministry of Health

kamada ltd, israel - japanese encephalitis purified inactivated vaccine - suspension for injection - japanese encephalitis purified inactivated vaccine 6 au / 0.5 ml - encephalitis, japanese, inactivated, whole virus - ixiaro is indicated for active immunization against japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

USA - engelsk - NLM (National Library of Medicine)

valneva scotland ltd. - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - ixiaro is a vaccine indicated for the prevention of disease caused by japanese encephalitis virus (jev). ixiaro is approved for use in individuals 2 months of age and older. severe allergic reaction (e.g., anaphylaxis) after a previous dose of ixiaro, any other japanese encephalitis virus vaccine, or any component of ixiaro, including protamine sulfate, is a contraindication to administration of ixiaro [see description (11)]. alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with ixiaro is considered. pregnancy category b. reproduction studies have been performed in female rats at doses approximately 300-fold excess relative to the projected human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to ixiaro. there are, however, no adequate and well‑controlled

Malta - engelsk - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - tick, borne encephalitis, virus - suspension for injection - tick-borne encephalitis virus 1,2 - vaccines

Malta - engelsk - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - tick, borne encephalitis, virus - suspension for injection in pre-filled syringe - tick-borne encephalitis virus 1,2 0.5 ml - vaccines

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - japanese encephalitis virus, quantity: 6 agu - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate; water for injections - jespect is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect is indicated for persons who work with je virus in laboratories and in industry.